Phase II multicenter pilot study of safety, efficacy, and immune cell profiling in advanced hepatocellular carcinoma (HCC) on combination of sorafenib (SOR) plus nivolumab (NIVO).

被引：4
|
作者：
Keenan, Bridget
Griffith, Madeline J.
Bauer, Kelly
Bracci, Paige M.
Behr, Spencer
Umetsu, Sarah E.
Gordan, John Dozier
Ngo, Zoe
Iqbal, Syma
Hanna, Diana L.
Venook, Alan P.
El-Khoueiry, Anthony B.
Fong, Lawrence
Kelley, Robin Kate
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA
[5] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[6] USC Norris Comprehens Canc Ctr, Keck Sch Med, Div Med Oncol, Los Angeles, CA USA
[7] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.TPS464
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS464
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A PILOT STUDY OF THE COMBINATION OF SORAFENIB PLUS NIVOLUMAB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC): SAFETY, EFFICACY, AND IMMUNE CELL PROFILING IN CHILD PUGH A AND B COHORTS
    Keenan, Bridget
    Le, Bryan Khuong
    Harris, Quincy
    Chen, Jocelin
    Cheung, Alexander
    Fan, Zenghua
    Lara, Frances
    Gordan, John
    Bracci, Paige
    Behr, Spencer
    Fong, Lawrence
    Venook, Alan
    Kim, Edward
    Kelley, Robin
    HEPATOLOGY, 2024, 80 : S748 - S748
  • [2] Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.
    Crocenzi, Todd S.
    El-Khoueiry, Anthony B.
    Yau, Thomas Cheung
    Melero, Ignacio
    Sangro, Bruno
    Kudo, Masatoshi
    Hsu, Chiun
    Trojan, Jorg
    Kim, Tae -You
    Choo, Su -Pin
    Meyer, Tim
    Kang, Yoon-Koo
    Yeo, Winnie
    Chopra, Akhil
    Baakili, Adyb
    Dela Cruz, Christine Marie
    Lang, Lixin
    Neely, Jaclyn
    Welling, Theodore
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Phase II trial of temsirolimus (TEM) plus sorafenib (SOR) in hepatocellular carcinoma (HCC)
    Kelley, Robin Kate
    Nimeiri, Halla Sayed
    Gordan, John Dozier
    Hwang, Jimmy
    McWhirter, Ryan M.
    Kanakamedala, Advaita
    Atreya, Chloe Evelyn
    Kulik, Laura
    Kircher, Sheetal
    Mulcahy, Mary Frances
    Benson, Al Bowen
    Venook, Alan P.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [4] Efficacy and safety of a phase II study of sorafenib plus gemcitabine in advanced hepatocellular carcinoma.
    Srimuninnimit, V.
    Sriuranpong, V.
    Suwanvecho, S.
    Soparattanapaisarn, N.
    Ithimakin, S.
    Akewanlop, C.
    Tanasanvimon, S.
    Parinyanitikul, N.
    Kiatikajornthada, N.
    Suwanrusme, H.
    Chaiyarat, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Phase I trial of temsirolimus (TEM) plus sorafenib (SOR) in advanced hepatocellular carcinoma (HCC)
    Kelley, R. K.
    Nimeiri, H. S.
    Vergo, M. T.
    Chia, K.
    Mulcahy, M. F.
    Bergsland, E. K.
    Ko, A. H.
    Munster, P. N.
    Benson, A. B.
    Venook, A. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [6] A phase I trial of the combination of temsirolimus (TEM) and sorafenib (SOR) in advanced hepatocellular carcinoma (HCC)
    Kelley, R. K.
    Nimeiri, H. S.
    Vargo, M. T.
    Bergsland, E. K.
    Ko, A. H.
    Munster, P. N.
    Reinert, A.
    Mulcahy, M. F.
    Benson, A. B.
    Venook, A. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Perspective Phase II Study of Combination Sorafenib Plus Mitomycin-C in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
    Dima, G.
    Lucia, M.
    La Gattuta, G.
    Toscano, R.
    Olivito, V.
    Talarico, R.
    Cervo, G. L.
    Filippelli, G.
    ONCOLOGY, 2009, 77 : 142 - 143
  • [8] PERSPECTIVE PHASE II STUDY OF COMBINATION SORAFENIB PLUS MITOMYCIN-C IN THE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
    Gianluca, Dima
    Maria, Lucia
    Gaetana, La Gattuta
    Rosa, Toscano
    Virginia, Olivito
    Rosa, Talarico
    Luca, Cervo Gian
    Gianfranco, Filippelli
    ANNALS OF ONCOLOGY, 2009, 20
  • [9] Perspective phase II study of combination sorafenib plus Mitomycin-C in the treatment of advanced hepatocellular carcinoma (HCC)
    Dima, G.
    Lucia, M.
    La Gattuta, G.
    Toscano, R.
    Filippelli, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 49 - 49
  • [10] Phase Ib/II study of sorafenib (SOR) and pembrolizumab (PEM) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Iyer, Renuka
    Sonti, Sahithi
    Mahalingam, Devalingam
    Mukherjee, Sarbajit
    Chakraborty, Sayan
    Attwood, Kristopher
    George, Anthony
    Maguire, Orla
    Minderman, Hans
    Fountzilas, Christos
    CANCER RESEARCH, 2024, 84 (07)
12345